Partnership combines Caris’ somatic and Ambry’s germline testing strengths to provide clinicians with unique information about the molecular and genetic components of a patient’s cancer
Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, and
FDA approves Kisqali for early high-risk breast cancer treatment. Learn about this new treatment option and its benefits for patients.
Download Slides: https://oncologytube.com/slides-fda-approves-kisqali-ribociclib-for-early-high-risk-breast-cancer/The FDA has approved Kisqali (ribociclib) …
Promising results from the TIGIT combination therapy trial presented at ESMO 2024. Discover the potential of this treatment for lung cancer.
In this video, we explore the FDA approval of Genentech’s Tecentriq Hybreza, the first subcutaneous anti-PD-(L)1 immunotherapy for cancer. Approved on Septem…
AVEO Oncology, a subsidiary of LG Chem, has announced the acceptance of its Phase 3 TiNivo-2 trial for a Proffered Paper oral presentation at the…
Dr. Nathalie M. Johnson, MD, discusses the importance of adopting ctDNA testing in breast cancer management. Find out how it can benefit patients with high-risk…
Exciting news in endometrial cancer treatment: FDA approves dostarlimab-gxly for broader patient population. Learn about the clinical trial and its positive results.
Discover the problem of underutilization of genetic testing in cancer. Find out how it can lead to missed opportunities for early intervention.
Introduction On August 2, 2024, the FDA granted accelerated approval to afamitresgene autoleucel (TECELRA) for treating adults with unresectable or metastatic synovial sarcoma. This approval…
Exciting news in endometrial cancer treatment: FDA approves dostarlimab-gxly for broader patient population. Learn about the clinical trial and its positive results.
